{"ticker": {"uuid": "e0c8e251-4234-4306-b2cd-d3b777cd031c", "symbol": "NBP", "name": "NovaBridge Biosciences", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "NovaBridge Biosciences (NBP) Holds Near Support Amid Modest Pullback - Combination Correction", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOa0xLdzN4ZmpRaVJjVFNhU1Z5UXAxOEViRnVoR08tei13Q0E5UTBCVndsSHJOUmJ3YlUwWGFKbmp6ZURZc1AtbGgyQkZBU2s3Wk1UZkhUeFpYV1lWcTgzdWRJQWI4LUFJZE1fb3dQRFJBOE4wR056OXVQczBqejFpbnJfdGQzUzhKQ0FmY015ei1tcW11ZllEd3U4d0RNUVdBdzhsMmsyeTZkNDdB?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-19T23:33:06+00:00", "published_display": "19 Jul 2026 23:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) Holds Near Support as Modest Decline Continues - GEX Level", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPTUV0aUZfSVBoblhnV2k4d09NQTJSQkxrakhQalo4UG45aVFjS1owUnFuazBlWXJ4b2hPN0c0ZmVtdzZHcDVjb1A5SHlvdTlpeDUtaVB5ZHROMV8zbFQ0MEF5NG1mZGtYTzFNdVhreG5icVJZZ2c0ZkNfZ2EyTWplMFBHRUpncm9JeWJDVTVGa05sSDZ1ZzNsNXRDcTRfQUhjME5kNk9BRHdoc09xYXc1NVdsZmtpZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-19T15:36:40+00:00", "published_display": "19 Jul 2026 15:36", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences Launches 2026 Omnibus Share Incentive Plan", "summary": "NovaBridge Biosciences has launched a new 2026 Omnibus Share Incentive Plan, replacing previous equity compensation schemes with a single framework. The plan authorizes the issuance of up to 11,960,000 ordinary shares initially and aims to attract and retain talent through stock ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3347168/novabridge-biosciences-launches-2026-omnibus-share-incentive-plan/", "source_name": "The Globe and Mail", "published_at": "2026-07-18T10:41:09", "published_display": "18 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) sets 2026 equity plan with 11.96M shares", "summary": "NovaBridge Biosciences has established a new 2026 Omnibus Share Incentive Plan, effective July 13, 2026, which initially reserves up to 11.96 million ordinary shares (equivalent to 5.2 million American Depositary Shares). The plan succeeds previous incentive plans and includes an", "url": "https://www.stocktitan.net/sec-filings/NBP/6-k-nova-bridge-biosciences-current-report-foreign-issuer-1a7b1205348e.html", "source_name": "Stock Titan", "published_at": "2026-07-17T10:09:50", "published_display": "17 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NovaBridge Biosciences (NBP) awards 949,050 long-dated stock options to its CCO", "summary": "NovaBridge Biosciences (NBP) has awarded its Chief Commercial Officer, Mark Arnold Hagler, 949,050 employee share options. These options, exercisable for American Depositary Shares (ADS) at $1.93 per ADS, vest in four equal annual installments starting April 17, 2027, and expire ", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-63aea2260b89.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:40:45", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) awards 254,780 employee share options to General Counsel", "summary": "NovaBridge Biosciences (NBP) has granted its General Counsel, Lin Liwei Lorraine, 254,780 2025 Employee Share Options. These options, with an exercise price of $1.93 per American Depositary Share (ADS), will vest over five years, with an initial 40% vesting on February 1, 2026, a", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-9156d62784d8.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:40:45", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Idorsia locks in new CEO after shakeup\u2014Chutes & Ladders", "summary": "Idorsia has appointed Roland Wandeler as its new CEO, effective October 1, following the departure of former chief Srishti Gupta. Gupta, who left Idorsia in March, has since been named CEO of NovaBridge BioSciences. Additionally, Muna Therapeutics has brought in Michel Detheux as", "url": "https://www.fiercebiotech.com/biotech/chutes-ladders-idorsia-locks-new-ceo-after-shakeup", "source_name": "Fierce Biotech", "published_at": "2026-07-10T12:39:48", "published_display": "10 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge (NBP) CEO awarded 3M options vesting over four years", "summary": "NovaBridge Biosciences' CEO, Srishti Gupta, was granted 3,000,000 employee share options with an exercise price of $2.01 per ADS-equivalent. These options will vest in four equal annual installments starting on July 1, 2026, and will expire on July 6, 2036. This grant serves as a", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-ee00e157996b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:35", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) CEO Srishti Gupta files initial insider ownership statement", "summary": "NovaBridge Biosciences CEO Srishti Gupta has filed an initial statement of beneficial ownership (Form 3) as an insider of the company. The filing indicates her role as Director and Chief Executive Officer but reports no equity transactions, derivative positions, or reportable hol", "url": "https://www.stocktitan.net/sec-filings/NBP/form-3-nova-bridge-biosciences-initial-statement-of-beneficial-owners-3d643677ce0f.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:35", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences SVP sells $3,991 in ordinary shares", "summary": "NovaBridge Biosciences Senior Vice President of Clinical Development, Xu Cong Claire, sold 4,485 ordinary shares for $3,991. This transaction followed her acquisition of 12,432 ordinary shares through vested restricted share units. The company has also recently received Fast Trac", "url": "https://www.investing.com/news/insider-trading-news/novabridge-biosciences-svp-sells-3991-in-ordinary-shares-93CH-4780585", "source_name": "Investing.com", "published_at": "2026-07-08T00:10:45", "published_display": "08 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) SVP exercises RSUs and sells Ordinary Shares in Form 4 filing", "summary": "Xu Cong Claire, SVP, Clinical Development at NovaBridge Biosciences (NBP), reported exercising Restricted Share Units (RSUs) and selling Ordinary Shares. On July 4, 2026, she converted 5,405 RSUs, equivalent to 5,405 American Depositary Shares (ADSs), into 12,432 Ordinary Shares.", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-c4b67f2c1f27.html", "source_name": "Stock Titan", "published_at": "2026-07-08T00:10:45", "published_display": "08 Jul 2026 00:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge: Rebranded, Repackaged, But Far From De-Risked (NASDAQ:NBP)", "summary": "NovaBridge (NBP), formerly I-Mab, has been rebranded but still faces significant risks, leading to a Sell rating. The lead asset, givastomig, has limited market opportunity, intense competition, and is only 50% owned by NBP. The company's high cash burn and negative risk-adjusted", "url": "https://seekingalpha.com/article/4919853-novabridge-rebranded-repackaged-but-far-from-de-risked", "source_name": "Seeking Alpha", "published_at": "2026-07-04T15:54:40", "published_display": "04 Jul 2026 15:54", "sentiment": "negative", "sentiment_pct": 26, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NBP - NovaBridge Biosciences ADR Latest SEC Filings", "summary": "This article provides the latest SEC filings for NovaBridge Biosciences ADR (NBP), including key financial data, stock performance metrics, and insider/institutional ownership details. As of July 2, the stock closed at $2.14, up 7.54%, with a market cap of $246.91 million. The fi", "url": "https://finviz.com/stock?t=NBP&ta=1&p=d&ty=lf&r=m6&page=10", "source_name": "Finviz", "published_at": "2026-07-02T16:12:46", "published_display": "02 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reversal Of Fortune For NovaBridge Biosciences Insiders Who Made A US$5.09m Purchase", "summary": "This article analyzes recent insider buying activity at NovaBridge Biosciences. Despite a significant US$5.09 million purchase by insiders over the last year, the stock has dropped 15%, suggesting a potential \"reversal of fortune.\" The article emphasizes that while insider buying", "url": "https://news.futunn.com/en/post/75339738/reversal-of-fortune-for-novabridge-biosciences-insiders-who-made-a", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-01T16:12:46", "published_display": "01 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fu Wei at NovaBridge (NBP) awarded RSUs and long-dated options", "summary": "NovaBridge Biosciences director Fu Wei has been awarded significant equity compensation, including 1,010,100 Restricted Share Units (RSUs) and three tranches of 2025 Employee Share Options. The RSUs vest over two years in equal annual installments starting June 29, 2027, while th", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-c7f7a071b0a3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T03:10:56", "published_display": "01 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novabridge Biosciences Announces Appointment of Srishti Gupta as Member of the Board of Directors, Effective July 1, 2026", "summary": "Novabridge Biosciences has announced the appointment of Dr. Srishti Gupta to its Board of Directors, effective July 1, 2026. Dr. Gupta brings over two decades of leadership experience in biopharmaceuticals, global health, and strategy, including her recent role as CEO of Idorsia ", "url": "https://www.marketscreener.com/news/novabridge-biosciences-announces-appointment-of-srishti-gupta-as-member-of-the-board-of-directors-e-ce7f5fded088f42d", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T03:10:56", "published_display": "30 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences appoints Srishti Gupta as CEO", "summary": "NovaBridge Biosciences has announced the appointment of Srishti Gupta as its new Chief Executive Officer. This leadership change is expected to guide the company's strategic direction and innovation in the biosciences sector. Gupta's appointment signals a new chapter for NovaBrid", "url": "https://www.msn.com/en-us/money/companies/novabridge-biosciences-appoints-srishti-gupta-as-ceo/ar-AA26MTOY", "source_name": "MSN", "published_at": "2026-06-29T14:09:26", "published_display": "29 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) Appoints Srishti Gupta as New CEO", "summary": "NovaBridge Biosciences (NBP) has appointed Srishti Gupta as its new CEO and board member, effective July 1, 2026. Gupta's appointment is expected to drive the company's strategic objectives, particularly in advancing its oncology pipeline with givastomig and exploring new partner", "url": "https://www.gurufocus.com/news/8936046/novabridge-biosciences-nbp-appoints-srishti-gupta-as-new-ceo", "source_name": "GuruFocus", "published_at": "2026-06-29T12:41:11", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences Names Dr. Srishti Gupta CEO to Lead Clinical Development Strategy", "summary": "NovaBridge Biosciences has appointed Dr. Srishti Gupta as its new CEO, effective July 1, 2026, to steer the company's clinical development strategy and foster strategic partnerships. Dr. Gupta will focus on advancing lead oncology candidate givastomig towards regulatory registrat", "url": "https://www.citybiz.co/article/866854/novabridge-biosciences-names-dr-srishti-gupta-ceo-to-lead-clinical-development-strategy/", "source_name": "citybiz", "published_at": "2026-06-29T12:41:10", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer", "summary": "NovaBridge Biosciences has appointed Dr. Srishti Gupta as its new Chief Executive Officer and a member of its Board of Directors, effective July 1, 2026. Dr. Gupta, who has over two decades of leadership experience in biopharmaceuticals and global health, will focus on advancing ", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318837/0/en/novabridge-biosciences-appoints-dr-srishti-gupta-as-chief-executive-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T11:09:26", "published_display": "29 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge taps physician-executive Dr. Gupta as CEO July 1", "summary": "NovaBridge Biosciences has appointed Dr. Srishti Gupta as its new CEO and a board member, effective July 1, 2026. Dr. Gupta, a physician-executive with over two decades of experience, will focus on advancing key drug candidates, expanding the ophthalmology franchise, and building", "url": "https://www.stocktitan.net/news/NBP/nova-bridge-biosciences-appoints-dr-srishti-gupta-as-chief-executive-7od2vbleiz9v.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:41:11", "published_display": "29 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leadership shake-up at NovaBridge (Nasdaq: NBP) as Srishti Gupta becomes CEO", "summary": "NovaBridge Biosciences (Nasdaq: NBP) has announced a significant leadership transition, appointing Dr. Srishti Gupta as the new Chief Executive Officer and a member of the Board of Directors, effective July 1, 2026. She succeeds Xi-Yong (Sean) Fu, who will step down but remain as", "url": "https://www.stocktitan.net/sec-filings/NBP/6-k-nova-bridge-biosciences-current-report-foreign-issuer-4a0a3f9d35bd.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:41:11", "published_display": "29 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of NovaBridge Biosciences \u2013 NASDAQ:NBP", "summary": "This article provides financial information for NovaBridge Biosciences (NASDAQ: NBP), specifically focusing on its forward price-to-earnings ratio. The content indicates market and company data provided by various financial services. The article appears to be a stub or specific d", "url": "https://www.tradingview.com/symbols/NASDAQ-NBP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:39:20", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NovaBridge Biosciences \u2013 NASDAQ:NBP", "summary": "This article displays the \"Price to sales forward\" financial metric for NovaBridge Biosciences (NASDAQ: NBP). It is a direct data display from TradingView, showing the period, value, change, and change percentage for this specific financial indicator. The page indicates that the ", "url": "https://www.tradingview.com/symbols/NASDAQ-NBP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:21:25", "published_display": "27 Jun 2026 00:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences Sponsored ADR Actuals & Estimates (NASDAQ:NBP)", "summary": "This page provides access to financial actuals and analyst estimates for NovaBridge Biosciences (NASDAQ:NBP). Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-NBP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:10:25", "published_display": "26 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) grants options and RSUs to executive", "summary": "NovaBridge Biosciences (NBP) has granted new equity awards to its Chief Business Development Officer, Cao Sean Wuxiong. The awards include 181,290 employee share options with an exercise price of $1.53 per ADS, vesting only when the 30-trading-day weighted average ADS price reach", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-f265cafd23b0.html", "source_name": "Stock Titan", "published_at": "2026-06-24T23:39:05", "published_display": "24 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences CMO Dennis Andrew sells $5,606 in shares", "summary": "NovaBridge Biosciences' Chief Medical Officer, Dennis Phillip Andrew, sold 8,494 ordinary shares (represented by 3,693 ADSs) for a total of $5,606 on June 18, 2026. This transaction occurred after an acquisition of 23,695 ordinary shares (10,302 ADSs) on June 17, 2026, and also i", "url": "https://www.investing.com/news/insider-trading-news/novabridge-biosciences-cmo-dennis-andrew-sells-5606-in-shares-93CH-4754113", "source_name": "Investing.com", "published_at": "2026-06-23T11:40:38", "published_display": "23 Jun 2026 11:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) CMO sells shares while exercising RSUs", "summary": "NovaBridge Biosciences' Chief Medical Officer, Dennis Phillip Andrew, recently engaged in insider transactions, selling 8,494 Ordinary Shares at $0.66 each and exercising derivative awards for 10,302 Ordinary Shares represented by American Depositary Shares (ADSs). Following thes", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-5987a2fc7cbc.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:40:03", "published_display": "22 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences CMO Dennis Andrew sells $5,606 in shares By Investing.com", "summary": "NovaBridge Biosciences' Chief Medical Officer, Dennis Phillip Andrew, sold $5,606 worth of company shares on June 18, 2026, disposing of 8,494 ordinary shares at $0.66 per share. This transaction occurred after acquiring 23,695 ordinary shares on June 17, 2026, and also involved ", "url": "https://ca.investing.com/news/stock-market-news/novabridge-biosciences-cmo-dennis-andrew-sells-5606-in-shares-93CH-4702030", "source_name": "Investing.com Canada", "published_at": "2026-06-22T21:40:03", "published_display": "22 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novabridge Biosciences ADR (NBP) Institutional Confidence", "summary": "This article from TradingKey provides an overview of the institutional confidence in Novabridge Biosciences ADR (NBP). It lists major institutional shareholders and their recent activity, showing that several firms have significantly increased their holdings in NBP. The company's", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nbp/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:46", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novabridge Biosciences ADR (NBP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Novabridge Biosciences ADR (NBP). It indicates that the company has distributed $0.00 in dividends over the past five years and reports no data for stock splits. The current stock price for NBP is $1.485, r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nbp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:09:02", "published_display": "18 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novabridge Biosciences ADR (NBP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Novabridge Biosciences ADR (NBP), focusing on key metrics like P/E, P/B, P/S, and P/CF. However, it states that relevant data for these valuation ratios have not yet been disclosed by the company. The article also provides current st", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nbp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:33", "published_display": "18 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/novabridge-biosciences-receives-fda-fast-110000035.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T11:00:00+00:00", "published_display": "16 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/novabridge-present-2026-jefferies-global-110000902.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T11:00:00+00:00", "published_display": "28 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/novabridge-present-h-c-wainwright-110000749.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T11:00:00+00:00", "published_display": "12 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "NovaBridge's Givastomig Could Drive A Major Re-Rating (NASDAQ:NBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQNUlvS1hGSVRvUGhjbVpGU3RSTzNka3dVRHZnR3lpMUQ0LW1SV0JGOEoxeWRlNzdfSzdHXzJucjA4UWdDd0VjcFd4U25Telh5SjdWUnp5bmJEZWt6ekFocnlvSklRNTJSSzdYb1lOYktITW1DdVd6SDQ0bEhSRGpQa2hrVjRkMFNHU3VpYWlzNDhyYVYt?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bullish NovaBridge Biosciences Insider Buying Worth US$5.09m Yet To Pay Off", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Both individual investors who control a good portion of NovaBridge Biosciences (NASDAQ:NBP) along with institutions must be dismayed after last week's 13% decrease", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences American Depositary Shares (NBP) Stock Price Today: $1.85", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE5ua3VvMDczU0I5NmMtMEdleGt4WENFRkpzeUFaNXc2MXpnaVc5X3RrVzgxTWQyQVJXbWVLa2RYdkdfZ3htSkNWdnFCSlZ4SHhmczhGUUdR?oc=5", "source_name": "Gotrade", "published_at": "2026-02-02T12:46:58+00:00", "published_display": "02 Feb 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NBP Stock Price and Chart \u2014 NASDAQ:NBP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFBYell5SGV2amd0YlhwUVYxcnVNR09FalY3SmNLUnV2NHFaVkJhbElRVUJYQ190V1JxMWtIWXVFdjQwSW9Bc0xVcmY0V1o1amtEdkktMWNHUzFYMHM?oc=5", "source_name": "TradingView", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NASDAQ:NBP) Shares Could Be 41% Below Their Intrinsic Value Estimate", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "NovaBridge Biosciences (NBP) Holds Near Support Amid Modest Pullback - Combination Correction", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOa0xLdzN4ZmpRaVJjVFNhU1Z5UXAxOEViRnVoR08tei13Q0E5UTBCVndsSHJOUmJ3YlUwWGFKbmp6ZURZc1AtbGgyQkZBU2s3Wk1UZkhUeFpYV1lWcTgzdWRJQWI4LUFJZE1fb3dQRFJBOE4wR056OXVQczBqejFpbnJfdGQzUzhKQ0FmY015ei1tcW11ZllEd3U4d0RNUVdBdzhsMmsyeTZkNDdB?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-19T23:33:06+00:00", "published_display": "19 Jul 2026 23:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) Holds Near Support as Modest Decline Continues - GEX Level", "summary": "", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPTUV0aUZfSVBoblhnV2k4d09NQTJSQkxrakhQalo4UG45aVFjS1owUnFuazBlWXJ4b2hPN0c0ZmVtdzZHcDVjb1A5SHlvdTlpeDUtaVB5ZHROMV8zbFQ0MEF5NG1mZGtYTzFNdVhreG5icVJZZ2c0ZkNfZ2EyTWplMFBHRUpncm9JeWJDVTVGa05sSDZ1ZzNsNXRDcTRfQUhjME5kNk9BRHdoc09xYXc1NVdsZmtpZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-19T15:36:40+00:00", "published_display": "19 Jul 2026 15:36", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences Launches 2026 Omnibus Share Incentive Plan", "summary": "NovaBridge Biosciences has launched a new 2026 Omnibus Share Incentive Plan, replacing previous equity compensation schemes with a single framework. The plan authorizes the issuance of up to 11,960,000 ordinary shares initially and aims to attract and retain talent through stock ", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3347168/novabridge-biosciences-launches-2026-omnibus-share-incentive-plan/", "source_name": "The Globe and Mail", "published_at": "2026-07-18T10:41:09", "published_display": "18 Jul 2026 10:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) sets 2026 equity plan with 11.96M shares", "summary": "NovaBridge Biosciences has established a new 2026 Omnibus Share Incentive Plan, effective July 13, 2026, which initially reserves up to 11.96 million ordinary shares (equivalent to 5.2 million American Depositary Shares). The plan succeeds previous incentive plans and includes an", "url": "https://www.stocktitan.net/sec-filings/NBP/6-k-nova-bridge-biosciences-current-report-foreign-issuer-1a7b1205348e.html", "source_name": "Stock Titan", "published_at": "2026-07-17T10:09:50", "published_display": "17 Jul 2026 10:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) awards 949,050 long-dated stock options to its CCO", "summary": "NovaBridge Biosciences (NBP) has awarded its Chief Commercial Officer, Mark Arnold Hagler, 949,050 employee share options. These options, exercisable for American Depositary Shares (ADS) at $1.93 per ADS, vest in four equal annual installments starting April 17, 2027, and expire ", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-63aea2260b89.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:40:45", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) awards 254,780 employee share options to General Counsel", "summary": "NovaBridge Biosciences (NBP) has granted its General Counsel, Lin Liwei Lorraine, 254,780 2025 Employee Share Options. These options, with an exercise price of $1.93 per American Depositary Share (ADS), will vest over five years, with an initial 40% vesting on February 1, 2026, a", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-9156d62784d8.html", "source_name": "Stock Titan", "published_at": "2026-07-10T20:40:45", "published_display": "10 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Idorsia locks in new CEO after shakeup\u2014Chutes & Ladders", "summary": "Idorsia has appointed Roland Wandeler as its new CEO, effective October 1, following the departure of former chief Srishti Gupta. Gupta, who left Idorsia in March, has since been named CEO of NovaBridge BioSciences. Additionally, Muna Therapeutics has brought in Michel Detheux as", "url": "https://www.fiercebiotech.com/biotech/chutes-ladders-idorsia-locks-new-ceo-after-shakeup", "source_name": "Fierce Biotech", "published_at": "2026-07-10T12:39:48", "published_display": "10 Jul 2026 12:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge (NBP) CEO awarded 3M options vesting over four years", "summary": "NovaBridge Biosciences' CEO, Srishti Gupta, was granted 3,000,000 employee share options with an exercise price of $2.01 per ADS-equivalent. These options will vest in four equal annual installments starting on July 1, 2026, and will expire on July 6, 2036. This grant serves as a", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-ee00e157996b.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:35", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) CEO Srishti Gupta files initial insider ownership statement", "summary": "NovaBridge Biosciences CEO Srishti Gupta has filed an initial statement of beneficial ownership (Form 3) as an insider of the company. The filing indicates her role as Director and Chief Executive Officer but reports no equity transactions, derivative positions, or reportable hol", "url": "https://www.stocktitan.net/sec-filings/NBP/form-3-nova-bridge-biosciences-initial-statement-of-beneficial-owners-3d643677ce0f.html", "source_name": "Stock Titan", "published_at": "2026-07-08T20:40:35", "published_display": "08 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences SVP sells $3,991 in ordinary shares", "summary": "NovaBridge Biosciences Senior Vice President of Clinical Development, Xu Cong Claire, sold 4,485 ordinary shares for $3,991. This transaction followed her acquisition of 12,432 ordinary shares through vested restricted share units. The company has also recently received Fast Trac", "url": "https://www.investing.com/news/insider-trading-news/novabridge-biosciences-svp-sells-3991-in-ordinary-shares-93CH-4780585", "source_name": "Investing.com", "published_at": "2026-07-08T00:10:45", "published_display": "08 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) SVP exercises RSUs and sells Ordinary Shares in Form 4 filing", "summary": "Xu Cong Claire, SVP, Clinical Development at NovaBridge Biosciences (NBP), reported exercising Restricted Share Units (RSUs) and selling Ordinary Shares. On July 4, 2026, she converted 5,405 RSUs, equivalent to 5,405 American Depositary Shares (ADSs), into 12,432 Ordinary Shares.", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-c4b67f2c1f27.html", "source_name": "Stock Titan", "published_at": "2026-07-08T00:10:45", "published_display": "08 Jul 2026 00:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge: Rebranded, Repackaged, But Far From De-Risked (NASDAQ:NBP)", "summary": "NovaBridge (NBP), formerly I-Mab, has been rebranded but still faces significant risks, leading to a Sell rating. The lead asset, givastomig, has limited market opportunity, intense competition, and is only 50% owned by NBP. The company's high cash burn and negative risk-adjusted", "url": "https://seekingalpha.com/article/4919853-novabridge-rebranded-repackaged-but-far-from-de-risked", "source_name": "Seeking Alpha", "published_at": "2026-07-04T15:54:40", "published_display": "04 Jul 2026 15:54", "sentiment": "negative", "sentiment_pct": 26, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NBP - NovaBridge Biosciences ADR Latest SEC Filings", "summary": "This article provides the latest SEC filings for NovaBridge Biosciences ADR (NBP), including key financial data, stock performance metrics, and insider/institutional ownership details. As of July 2, the stock closed at $2.14, up 7.54%, with a market cap of $246.91 million. The fi", "url": "https://finviz.com/stock?t=NBP&ta=1&p=d&ty=lf&r=m6&page=10", "source_name": "Finviz", "published_at": "2026-07-02T16:12:46", "published_display": "02 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Reversal Of Fortune For NovaBridge Biosciences Insiders Who Made A US$5.09m Purchase", "summary": "This article analyzes recent insider buying activity at NovaBridge Biosciences. Despite a significant US$5.09 million purchase by insiders over the last year, the stock has dropped 15%, suggesting a potential \"reversal of fortune.\" The article emphasizes that while insider buying", "url": "https://news.futunn.com/en/post/75339738/reversal-of-fortune-for-novabridge-biosciences-insiders-who-made-a", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-01T16:12:46", "published_display": "01 Jul 2026 16:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fu Wei at NovaBridge (NBP) awarded RSUs and long-dated options", "summary": "NovaBridge Biosciences director Fu Wei has been awarded significant equity compensation, including 1,010,100 Restricted Share Units (RSUs) and three tranches of 2025 Employee Share Options. The RSUs vest over two years in equal annual installments starting June 29, 2027, while th", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-c7f7a071b0a3.html", "source_name": "Stock Titan", "published_at": "2026-07-01T03:10:56", "published_display": "01 Jul 2026 03:10", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novabridge Biosciences Announces Appointment of Srishti Gupta as Member of the Board of Directors, Effective July 1, 2026", "summary": "Novabridge Biosciences has announced the appointment of Dr. Srishti Gupta to its Board of Directors, effective July 1, 2026. Dr. Gupta brings over two decades of leadership experience in biopharmaceuticals, global health, and strategy, including her recent role as CEO of Idorsia ", "url": "https://www.marketscreener.com/news/novabridge-biosciences-announces-appointment-of-srishti-gupta-as-member-of-the-board-of-directors-e-ce7f5fded088f42d", "source_name": "www.marketscreener.com", "published_at": "2026-06-30T03:10:56", "published_display": "30 Jun 2026 03:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences appoints Srishti Gupta as CEO", "summary": "NovaBridge Biosciences has announced the appointment of Srishti Gupta as its new Chief Executive Officer. This leadership change is expected to guide the company's strategic direction and innovation in the biosciences sector. Gupta's appointment signals a new chapter for NovaBrid", "url": "https://www.msn.com/en-us/money/companies/novabridge-biosciences-appoints-srishti-gupta-as-ceo/ar-AA26MTOY", "source_name": "MSN", "published_at": "2026-06-29T14:09:26", "published_display": "29 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) Appoints Srishti Gupta as New CEO", "summary": "NovaBridge Biosciences (NBP) has appointed Srishti Gupta as its new CEO and board member, effective July 1, 2026. Gupta's appointment is expected to drive the company's strategic objectives, particularly in advancing its oncology pipeline with givastomig and exploring new partner", "url": "https://www.gurufocus.com/news/8936046/novabridge-biosciences-nbp-appoints-srishti-gupta-as-new-ceo", "source_name": "GuruFocus", "published_at": "2026-06-29T12:41:11", "published_display": "29 Jun 2026 12:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences Names Dr. Srishti Gupta CEO to Lead Clinical Development Strategy", "summary": "NovaBridge Biosciences has appointed Dr. Srishti Gupta as its new CEO, effective July 1, 2026, to steer the company's clinical development strategy and foster strategic partnerships. Dr. Gupta will focus on advancing lead oncology candidate givastomig towards regulatory registrat", "url": "https://www.citybiz.co/article/866854/novabridge-biosciences-names-dr-srishti-gupta-ceo-to-lead-clinical-development-strategy/", "source_name": "citybiz", "published_at": "2026-06-29T12:41:10", "published_display": "29 Jun 2026 12:41", "sentiment": "positive", "sentiment_pct": 76, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences Appoints Dr. Srishti Gupta as Chief Executive Officer", "summary": "NovaBridge Biosciences has appointed Dr. Srishti Gupta as its new Chief Executive Officer and a member of its Board of Directors, effective July 1, 2026. Dr. Gupta, who has over two decades of leadership experience in biopharmaceuticals and global health, will focus on advancing ", "url": "https://www.globenewswire.com/news-release/2026/06/29/3318837/0/en/novabridge-biosciences-appoints-dr-srishti-gupta-as-chief-executive-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T11:09:26", "published_display": "29 Jun 2026 11:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge taps physician-executive Dr. Gupta as CEO July 1", "summary": "NovaBridge Biosciences has appointed Dr. Srishti Gupta as its new CEO and a board member, effective July 1, 2026. Dr. Gupta, a physician-executive with over two decades of experience, will focus on advancing key drug candidates, expanding the ophthalmology franchise, and building", "url": "https://www.stocktitan.net/news/NBP/nova-bridge-biosciences-appoints-dr-srishti-gupta-as-chief-executive-7od2vbleiz9v.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:41:11", "published_display": "29 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leadership shake-up at NovaBridge (Nasdaq: NBP) as Srishti Gupta becomes CEO", "summary": "NovaBridge Biosciences (Nasdaq: NBP) has announced a significant leadership transition, appointing Dr. Srishti Gupta as the new Chief Executive Officer and a member of the Board of Directors, effective July 1, 2026. She succeeds Xi-Yong (Sean) Fu, who will step down but remain as", "url": "https://www.stocktitan.net/sec-filings/NBP/6-k-nova-bridge-biosciences-current-report-foreign-issuer-4a0a3f9d35bd.html", "source_name": "Stock Titan", "published_at": "2026-06-29T10:41:11", "published_display": "29 Jun 2026 10:41", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of NovaBridge Biosciences \u2013 NASDAQ:NBP", "summary": "This article provides financial information for NovaBridge Biosciences (NASDAQ: NBP), specifically focusing on its forward price-to-earnings ratio. The content indicates market and company data provided by various financial services. The article appears to be a stub or specific d", "url": "https://www.tradingview.com/symbols/NASDAQ-NBP/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:39:20", "published_display": "27 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of NovaBridge Biosciences \u2013 NASDAQ:NBP", "summary": "This article displays the \"Price to sales forward\" financial metric for NovaBridge Biosciences (NASDAQ: NBP). It is a direct data display from TradingView, showing the period, value, change, and change percentage for this specific financial indicator. The page indicates that the ", "url": "https://www.tradingview.com/symbols/NASDAQ-NBP/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T00:21:25", "published_display": "27 Jun 2026 00:21", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences Sponsored ADR Actuals & Estimates (NASDAQ:NBP)", "summary": "This page provides access to financial actuals and analyst estimates for NovaBridge Biosciences (NASDAQ:NBP). Users can explore reported financial data and compare actual results with average, high, and low estimates across various financial statements and valuation metrics. The ", "url": "https://www.tradingview.com/symbols/NASDAQ-NBP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T14:10:25", "published_display": "26 Jun 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) grants options and RSUs to executive", "summary": "NovaBridge Biosciences (NBP) has granted new equity awards to its Chief Business Development Officer, Cao Sean Wuxiong. The awards include 181,290 employee share options with an exercise price of $1.53 per ADS, vesting only when the 30-trading-day weighted average ADS price reach", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-f265cafd23b0.html", "source_name": "Stock Titan", "published_at": "2026-06-24T23:39:05", "published_display": "24 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences CMO Dennis Andrew sells $5,606 in shares", "summary": "NovaBridge Biosciences' Chief Medical Officer, Dennis Phillip Andrew, sold 8,494 ordinary shares (represented by 3,693 ADSs) for a total of $5,606 on June 18, 2026. This transaction occurred after an acquisition of 23,695 ordinary shares (10,302 ADSs) on June 17, 2026, and also i", "url": "https://www.investing.com/news/insider-trading-news/novabridge-biosciences-cmo-dennis-andrew-sells-5606-in-shares-93CH-4754113", "source_name": "Investing.com", "published_at": "2026-06-23T11:40:38", "published_display": "23 Jun 2026 11:40", "sentiment": "negative", "sentiment_pct": 42, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NBP) CMO sells shares while exercising RSUs", "summary": "NovaBridge Biosciences' Chief Medical Officer, Dennis Phillip Andrew, recently engaged in insider transactions, selling 8,494 Ordinary Shares at $0.66 each and exercising derivative awards for 10,302 Ordinary Shares represented by American Depositary Shares (ADSs). Following thes", "url": "https://www.stocktitan.net/sec-filings/NBP/form-4-nova-bridge-biosciences-insider-trading-activity-5987a2fc7cbc.html", "source_name": "Stock Titan", "published_at": "2026-06-22T21:40:03", "published_display": "22 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences CMO Dennis Andrew sells $5,606 in shares By Investing.com", "summary": "NovaBridge Biosciences' Chief Medical Officer, Dennis Phillip Andrew, sold $5,606 worth of company shares on June 18, 2026, disposing of 8,494 ordinary shares at $0.66 per share. This transaction occurred after acquiring 23,695 ordinary shares on June 17, 2026, and also involved ", "url": "https://ca.investing.com/news/stock-market-news/novabridge-biosciences-cmo-dennis-andrew-sells-5606-in-shares-93CH-4702030", "source_name": "Investing.com Canada", "published_at": "2026-06-22T21:40:03", "published_display": "22 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novabridge Biosciences ADR (NBP) Institutional Confidence", "summary": "This article from TradingKey provides an overview of the institutional confidence in Novabridge Biosciences ADR (NBP). It lists major institutional shareholders and their recent activity, showing that several firms have significantly increased their holdings in NBP. The company's", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nbp/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:46", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novabridge Biosciences ADR (NBP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical dividend and stock split information for Novabridge Biosciences ADR (NBP). It indicates that the company has distributed $0.00 in dividends over the past five years and reports no data for stock splits. The current stock price for NBP is $1.485, r", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nbp/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T09:09:02", "published_display": "18 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Novabridge Biosciences ADR (NBP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Novabridge Biosciences ADR (NBP), focusing on key metrics like P/E, P/B, P/S, and P/CF. However, it states that relevant data for these valuation ratios have not yet been disclosed by the company. The article also provides current st", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-nbp/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:40:33", "published_display": "18 Jun 2026 05:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/novabridge-biosciences-receives-fda-fast-110000035.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T11:00:00+00:00", "published_display": "16 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/novabridge-present-2026-jefferies-global-110000902.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T11:00:00+00:00", "published_display": "28 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Companies Like NovaBridge Biosciences (NASDAQ:NBP) Can Afford To Invest In Growth", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/novabridge-present-h-c-wainwright-110000749.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T11:00:00+00:00", "published_display": "12 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge's Givastomig Could Drive A Major Re-Rating (NASDAQ:NBP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQNUlvS1hGSVRvUGhjbVpGU3RSTzNka3dVRHZnR3lpMUQ0LW1SV0JGOEoxeWRlNzdfSzdHXzJucjA4UWdDd0VjcFd4U25Telh5SjdWUnp5bmJEZWt6ekFocnlvSklRNTJSSzdYb1lOYktITW1DdVd6SDQ0bEhSRGpQa2hrVjRkMFNHU3VpYWlzNDhyYVYt?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bullish NovaBridge Biosciences Insider Buying Worth US$5.09m Yet To Pay Off", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-31T07:00:00+00:00", "published_display": "31 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Both individual investors who control a good portion of NovaBridge Biosciences (NASDAQ:NBP) along with institutions must be dismayed after last week's 13% decrease", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences American Depositary Shares (NBP) Stock Price Today: $1.85", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE5ua3VvMDczU0I5NmMtMEdleGt4WENFRkpzeUFaNXc2MXpnaVc5X3RrVzgxTWQyQVJXbWVLa2RYdkdfZ3htSkNWdnFCSlZ4SHhmczhGUUdR?oc=5", "source_name": "Gotrade", "published_at": "2026-02-02T12:46:58+00:00", "published_display": "02 Feb 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NBP Stock Price and Chart \u2014 NASDAQ:NBP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiW0FVX3lxTFBYell5SGV2amd0YlhwUVYxcnVNR09FalY3SmNLUnV2NHFaVkJhbElRVUJYQ190V1JxMWtIWXVFdjQwSW9Bc0xVcmY0V1o1amtEdkktMWNHUzFYMHM?oc=5", "source_name": "TradingView", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NovaBridge Biosciences (NASDAQ:NBP) Shares Could Be 41% Below Their Intrinsic Value Estimate", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6wFBVV95cUxNT3gybjRKVUJ5ZTQtQ0tyVnJYNTRmTnNpOUJBZW5Da3c2RGZLbU4ycWhObVVTbGNPM3YzNnpUYmItbUhCZ3oxZTRGTHZnZTNwa3BQeE9qT2FyMWhCWkVUeG9uV1V2U3hZdVVMSzdVMlBEUThoZzF5SUVBNUY2dG01V3dCU3d4amNybG91WTZDaXdPZmxsdVgxdlVIcGdTQ0c5MDNsaHBZcGdibWI1bGpudm5TTlZNaEdxX2tpS2twSGtUSDJWZlZidHd1M3p1RGVjczhjcHFleFNvR1dDczRCOWsyTEpQdDlCTHNZ0gHwAUFVX3lxTFBBaEx0MjlzYWd0OXBvSzlDV0pqbWd5bjVHMFFXUndpbW1jVGQ5bW1LOWpxUUNvM3ROZE5qUFlGT0FZR09ENFJ5UWJtNkhNNDU5bTVwTy1jQjdCUldwcEhBS2ZtRDVkU1VYNTdFR2RjVWVfZG4yZ0FueDBmSnBWRDQ0NUxxUFpaOEgxai1zMkhVYm80VGhWX3ZxUnBqS3ZGQmhXRmR3ZVpHUW5SaEY2S0NubTB6SEJNNUJhaGpyTmktdWVYckxFSzREbEQ3alBGWmhPM2otMWFib2JGN3l5Tlc5WE9vMVVOaFhsc01kWjNpLQ?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-31T08:00:00+00:00", "published_display": "31 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "PR Newswire", "published_at": "2025-10-29T07:00:00+00:00", "published_display": "29 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 86, "total_relevant": 52, "sentiment_summary": {"positive": 12, "negative": 5, "neutral": 35, "score": 53, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 85, "events": [{"event": "general", "label": "Market update", "weight": 20.15, "count": 36}, {"event": "earnings", "label": "Earnings", "weight": 4.81, "count": 11}, {"event": "deals", "label": "Deals and strategy", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 0.9, "count": 1}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 12, "negative_events": 5}, "market_context": {"has_market_context": true, "latest_close": 1.78, "latest_week": "2026-07-17", "one_week_move": -6.3, "four_week_move": 18.7, "twelve_week_move": -27.3, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.150559, "market_dynamics_buy_signal": false, "relative_strength": -52.224861, "fair_value_gap": -14.3, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 38.6495, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-6.3% over one week, +18.7% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 11}, {"label": "Market source", "count": 6}, {"label": "simplywall.st", "count": 6}, {"label": "TradingView", "count": 5}, {"label": "GlobeNewswire", "count": 4}, {"label": "TradingKey", "count": 3}, {"label": "dars.gov.et", "count": 2}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 36}, {"label": "Earnings", "count": 11}, {"label": "Deals and strategy", "count": 2}, {"label": "Analyst action", "count": 1}, {"label": "Regulatory and legal", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "85/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-6.3% over one week, +18.7% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "NovaBridge Biosciences (NBP) Holds Near Support Amid Modest Pullback - Combination Correction"}], "updated_at": "2026-07-22T11:43:10.076047+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}